Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Ligand Pharm Latest News and Headlines for [[ item.sessionDateDisplayLong ]]
Ligand Inks Oncology Drug Discovery Deal With PhoreMost

Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.

SPPI : 8.48 (+3.54%)
LGND : 114.29 (+2.61%)
NVS : 91.30 (+1.72%)
AMGN : 181.61 (+1.81%)
Ligand Grants Preclinical Candidate Rights to UK-based Firm

Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.

LGND : 114.29 (+2.61%)
NVS : 91.30 (+1.72%)
SAGE : 182.39 (+1.45%)
AMGN : 181.61 (+1.81%)
Ligand Licenses VER250840 to Cumulus Oncology

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840,...

LGND : 114.29 (+2.61%)
AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

LGND : 114.29 (+2.61%)
GNMSF : 178.0700 (+1.26%)
AMAG : 9.15 (+1.22%)
FCSC : 1.99 (unch)
Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View

Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.

LGND : 114.29 (+2.61%)
MNK : 9.35 (+3.77%)
RHHBY : 34.8400 (+1.16%)
BMY : 47.79 (-0.87%)
Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss

Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.

MYL : 17.75 (+2.78%)
LGND : 114.29 (+2.61%)
TEVA : 8.36 (+1.95%)
FCSC : 1.99 (unch)
Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin...

LGND : 114.29 (+2.61%)
NOVN : 2.66 (-2.92%)
Watch for Ligand Pharm to Potentially Rebound After Falling 9.18% Yesterday

Ligand Pharm (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $115.25 to a high of $127.29. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $123.14...

LGND : 114.29 (+2.61%)
Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates

Ligand (LGND) delivered earnings and revenue surprises of -95.92% and 13.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

LGND : 114.29 (+2.61%)
Ligand: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Thursday reported first-quarter earnings of $666.3 million.

LGND : 114.29 (+2.61%)
Ligand Reports First Quarter 2019 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2019 and provided an operating forecast and program updates. Ligand...

LGND : 114.29 (+2.61%)
Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol

--Also reports recent results from clinician survey on radiocontrast agent selection and use

LGND : 114.29 (+2.61%)
Ligand Pharmaceuticals (LGND) Reports Next Week: Wall Street Expects Earnings Growth

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LGND : 114.29 (+2.61%)
Ligand to Report First Quarter 2019 Results on May 2nd

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2019 financial results on May 2, 2019. Ligand's CEO John Higgins, President and COO Matt Foehr...

LGND : 114.29 (+2.61%)
Shares of LGND Down 15.7% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Ligand Pharm (NASDAQ:LGND) on November 13th, 2018 at $152.60. In approximately 4 months, Ligand Pharm has returned 15.71% as of today's recent price of $128.62.

LGND : 114.29 (+2.61%)
Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics' ZULRESSO(TM) (brexanolone) Injection

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it will receive a $3 million milestone payment as a result of the U.S. Food and Drug Administration's (FDA) approval of Sage...

LGND : 114.29 (+2.61%)
SAGE : 182.39 (+1.45%)
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight

Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight

CARB : 23.60 (-0.88%)
EYES : 0.73 (+4.41%)
LGND : 114.29 (+2.61%)
CATB : 6.45 (+6.61%)
KEG : 1.74 (-2.25%)
Interesting LGND Put And Call Options For November 15th

Investors in Ligand Pharmaceuticals Inc saw new options become available this week, for the November 15th expiration. One of the key data points that goes into the price an option buyer is willing to...

LGND : 114.29 (+2.61%)
Insiders Bullish on Certain Holdings of MDY

A look at the weighted underlying holdings of the SPDR S&P MIDCAP 400 ETF (MDY) shows an impressive 13.1% of holdings on a weighted basis have experienced insider buying within the past six months. ...

LGND : 114.29 (+2.61%)
After Yesterday's Rally of 4.49% Shares Could Potentially Pullback

Ligand Pharm (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $119.03 to a high of $124.88. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of...

LGND : 114.29 (+2.61%)

Van Meerten Stock Picks

Cohen & Steers REIT ETF
My Pick of the Day is the Cohen & Steers REIT ETF (ICF).
ICF -0.53
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar